Effectiveness of Monoclonal Antibody Therapy for Preventing COVID-19 Hospitalization and Mortality in a Statewide Population.

ABSTRACT:

Background

Monoclonal antibody (MAB) treatments for COVID-19 received Emergency Use Authorization in the United States.

Methods

We used surveillance data from Rhode Island to conduct a retrospective, statewide cohort study to estimate the effectiveness of MABs for preventing hospitalization and death during periods when Alpha and Delta variants were predominant.

Results

From 1/17/2021-10/26/2021, 285 long-term congregate care (LTCC) residents and 3,113 non-congregate patients met our eligibility criteria and received MAB; they were matched to 285 and 6,226 controls, respectively. Among LTCC residents, 8.8% (25/285) of patients who received MAB were hospitalized or died compared to 25.3% (72/285) of those who did not receive MAB (adjusted difference=16.7%, 95% confiden

SUBMITTER: Chambers LC 

PROVIDER: S-EPMC11457867 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature